Research Peptide · 30mg × 10 vials
it's Selank with both ends protected so your body can't break it down as fast, giving the same calm-focus-immune effect but with fewer doses per day.
NA-Selank Amidate is the chemically stabilized cousin of native Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), which is itself a synthetic analog of tuftsin, an endogenous immunomodulatory tetrapeptide cleaved from IgG. Two modifications are stacked onto the parent heptapeptide. First, the N-terminus is acetylated (an acetyl group is added to the front of the chain), which blocks aminopeptidase cleavage and slows enzymatic breakdown in serum and mucosal tissue. Second, the C-terminus is amidated (the free carboxylic acid is converted to an amide), which blocks carboxypeptidase cleavage at the back of the molecule and also nudges up lipophilicity, theoretically helping blood-brain-barrier penetration. Capping both ends of the peptide gives it a meaningfully longer functional window than native Selank, which is otherwise degraded within minutes. The pharmacologically active core, and therefore the downstream mechanism, is unchanged from native Selank: GABA-A receptor expression upregulation for the anxiolytic effect (calm without binding the benzodiazepine site, hence no sedation, tolerance, or dependence), a serotonergic arm that raises brain serotonin metabolism via 5-HIAA, hippocampal BDNF upregulation for the mood/neuroplasticity layer, and residual tuftsin-derived immunomodulatory activity (interferon and cytokine modulation). In practice NA-Selank does exactly what Selank does at the receptor level — it just does it for longer per dose, which is why the dosing schedule collapses from 2-3 times daily on native Selank to once or twice daily on NA-Selank. In plain language: it's Selank with both ends protected so your body can't break it down as fast, giving the same calm-focus-immune effect but with fewer doses per day.
Typical dose ranges by experience level — educational reference. Message us and we tailor it to you.
At 10 mg/ml (30 mg vial in 3 ml BAC), 300 mcg = 0.03 ml = 3 IU on a U-100 syringe. The dose per administration is similar to native Selank; the change is frequency — once daily instead of 2-3 times daily. First-dose acute anxiolytic feel is similar to native but smoother in onset (the longer functional window means a slower ramp, less of a "did it kick in" question). Full baseline shift takes 7-14 days, same as native.
This is the band that gets the most NA-Selank retention in community reports. The once-daily cadence is the actual selling point — customers who hated the 2-3×/day intranasal schedule on native Selank settle into NA-Selank comfortably. SubQ equivalent runs 200-500 mcg once daily for users who prefer the route. No need for the matched split-dosing native Selank required.
Above ~1 mg/day there is no documented additional benefit — the dose-response plateaus the same way native Selank does. Advanced use is more about stack design (paired N-Acetyl Semax for a matched long-acting neuropeptide stack, paired DSIP for sleep, paired PE 22-28 for additional mood support) than dose escalation. The flagship advanced use case is the NA-Semax + NA-Selank "amidate stack" — same dosing cadence for both, a single combined morning dose covers the day.
Straight talk — what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines — tap any to read the source.
original Russian clinical anxiety trial, native Selank
Read study ↗PubMedMedvedev et al, Comparative analysis of Selank and medazepam in anxiety disorder, Zh Nevrol Psikhiatr 2007head-to-head against benzodiazepine medazepam, comparable efficacy without sedation or cognitive impairment
Read study ↗PubMedKost et al, Peptide selank as an analog of tuftsin and its effects on the GABAergic system, Bull Exp Biol Med 2001mechanism, GABA-A receptor expression
Read study ↗PubMedVolkova et al, Selank administration affects expression of genes involved in GABAergic neurotransmission, Front Pharmacol 2016gene expression and GABAergic neurotransmission
Read study ↗PubMedKolomin et al, Transcriptomic responses to Selank in rat hippocampus, Genom Data 2014BDNF and neuroplasticity gene expression
Read study ↗PubMedSemenova et al, Selank and BDNF expression, Bull Exp Biol Med 2010BDNF upregulation, mechanism carries over to NA-Selank
Read study ↗Aggregated sentiment from public forums & socials — real-world reports, not individual endorsements.
"Same Selank, fewer doses" is the consensus framing on r/Nootropics and r/Peptides. Users who ran native Selank and switched report the subjective per-dose effect is indistinguishable; the win is the schedule collapse.
Smoother onset: native Selank can have a noticeable "kick in" point within 30 min; NA-Selank is described as a softer ramp over 60-90 min because the longer functional window flattens the peak.
Mild headache on the first 1-2 doses: occasional, same as native, usually resolves.
Nasal dryness on continuous intranasal use: same management as native (saline rinse, rotate to SubQ).
"Feels like nothing dramatic" still applies — the anxiolytic effect is the absence of anxiety rather than a buzz, same as native.
No reports of withdrawal or rebound on stopping cold.
Route: intranasal (primary research route), SubQ as a secondary route
Injection site: N/A for the primary intranasal route. If SubQ — abdomen or outer thigh with a 31G insulin pin, rotate sites.
Storage: refrigerated, stable ~30 days reconstituted. Lyophilized vials room-temp short-term, refrigerate for long storage. Same handling as native Selank.
Notes: NA-Selank is more concentrated per vial than native Selank (30 mg vs 5 or 10 mg), so the reconstitution math is the most common dosing mistake customers make. Default to 3 ml BAC for cleaner measurement. Once-daily morning dosing is the standard NA-Selank protocol — the whole point of the molecule is that you do not need the 2-3 times daily schedule that native Selank runs.